Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.170 +0.080 (+7.33%)
Streaming Delayed Price Updated: 12:31 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why Clearmind Medicine Stock Is Moving Higher ↗
Clearmind Medicine shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development. 
Via Benzinga
Topics Intellectual Property
News headline image
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Clearmind Applies to Cease Being a Reporting Issuer in Canada
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More ↗
 
Via Benzinga
News headline image
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗
 
Via Benzinga
News headline image
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine CEO Issues Letter to Shareholders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More ↗
 
Via Benzinga
News headline image
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗
 
Via Benzinga
News headline image
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗
 
Via Benzinga
Topics Economy
News headline image
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket ↗
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. 
Via Benzinga
News headline image
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review ↗
 
Via Benzinga
News headline image
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors ↗
 
Via Benzinga
News headline image
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗
 
Via Benzinga
News headline image
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds ↗
Patent applications by Clearmind Medicine for novel compositions in collaboration with SciSparc. Clearmind's CEO, highlights the significant expansion of IP protection. 
Via Benzinga
Topics Intellectual Property
News headline image
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents ↗
SciSparc & Clearmind file patents for LSD, psilocybin, DMT blends, advancing psychedelic therapeutics for mental health. 
Via Benzinga
Topics Intellectual Property
News headline image
What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock? ↗
SciSparc Ltd. and Clearmind Medicine Inc. shares are trading higher Tuesday after the companies announced the submission of three international patent applications as part of the ongoing collaboration... 
Via Benzinga
Topics Intellectual Property
News headline image
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.